The price of Humira per injection in 2024 varies depending on factors such as insurance coverage, dosage, and location. Without specific insurance details, providing an exact figure is not possible. However, the list price for a single-dose prefilled syringe or pen can range from approximately $6,500 to $7,000 or more. [1]
What drives Humira's cost?
Humira's high cost is influenced by its development expenses, manufacturing complexity, and the significant clinical benefits it offers for various autoimmune conditions. The drug's patent protection has also historically allowed for premium pricing. [2]
How does insurance affect Humira costs?
Insurance plans significantly impact out-of-pocket expenses for Humira. Patients with comprehensive prescription drug coverage may pay substantially less than the list price through co-pays or co-insurance. Conversely, those with less robust coverage or high-deductible plans could face higher costs. Patient assistance programs offered by the manufacturer may also help reduce financial burdens for eligible individuals. [3]
When does Humira's patent expire?
Humira's primary patents have expired or are nearing expiration in key markets, paving the way for biosimilar competition. In the United States, the last key patents expired around 2023. [4]
What are the alternatives to Humira?
With patent expirations, biosimilars of Humira are becoming available, offering potentially lower-cost alternatives. Additionally, other biologic drugs and non-biologic treatments exist for the conditions Humira treats, such as adalimumab biosimilars, infliximab, etanercept, and JAK inhibitors. [5]
How do Humira biosimilars compare?
Humira biosimilars are highly similar to the reference product in terms of safety, efficacy, purity, and potency. They are approved for the same indications as Humira. The primary difference is typically in their pricing, with biosimilars generally expected to be more affordable. [5]
Who makes Humira and its biosimilars?
Humira is manufactured by AbbVie. Several companies have developed and are marketing biosimilars of adalimumab, including Amgen (Amjevita), Sandoz (Hyrimoz), and Boehringer Ingelheim (Cyltezo), among others. [5]
Sources:
[1] https://www.drugpatentwatch.com/drug/humira/adalimumab
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/humira/adalimumab
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/drug/humira/adalimumab